Preventing hepatitis C virus transmission in Australians who inject drugs

---

• 1.
• Seeff AB. Natural history of hepatitis C. Hepatology 1997; 26 (3 Suppl): 215-285.
• 2.
• Zekry A, Whiting P, Crawford D, et al. Long term outcome of hepatitis C virus infection post liver transplantation. The Australian and New Zealand experience [abstract]. J Gastroenterol Hepatol 1999; 14: A171.
• 3.
• Roberts SK, Sulaiman N, Giles G, et al. Rising incidence and risk factors for hepatocellular carcinoma in Victoria [abstract]. J Gastroenterol Hepatol 1999; 14: A194.
• 4.
• Dore G, Kaldor J, McCaughan G. Systematic review of the role of polymerase chain reaction in defining infectiousness among people with hepatitis C virus. BMJ 1997; 315: 333-337.
• 5.
• Crofts N, Thompson S, Kaldor J. Epidemiology of the hepatitis C virus. Communicable Diseases Intelligence Technical Report Series No. 3. Canberra: National Centre for Disease Control, Commonwealth Department of Health and Aged Care, and Communicable Disease Network Australia and New Zealand, May 1999.
• 6.
• Australian National Council on AIDS and Related Diseases Hepatitis C Sub-Committee. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of NSW, August 1998.
• 7.
• MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Med J Aust 2000; 172: 57-61.
• 8.
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (Suppl 1): 1125-1215.
• 9.
• Hepatitis C National Data Base Project. Final report 1999. Newcastle: Hepatitis C National Data Base, 1999.
• 10.
• Kochbar DM. Effects of exposure to high concentrations of ribavirin in devloping embryos. Pediatr Infect Dis J 1990; 9 (9 Suppl): S88-S90.